Comparable Renal Function at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: Results of a Randomized Multicenter Trial in Renal Transplantation
Table 2
Measurements of renal function at month 6.
Tacrolimus/Sirolimus
Tacrolimus/MMF
Creatinine Clearance (Cockcroft-Gault), mean (SE), mL/min
Patients completing the study
250
66.4 (1.4)
266
65.2 (1.3)
Patients with month 6
289
64.6 (1.3)
289
63.7 (1.3)
Patients with DGF
48
56.1 (20.0)
38
60.5 (22.9)
Patients without DGF
241
66.3 (21.5)
251
64.2 (21.9)
Creatinine Clearance (MDRD-4), mean (SD), mL/min
Patients completing the study
250
55.3 (1.2)
266
54.0 (1.2)
Patients with month 6
289
53.9 (1.1)
289
53.0 (1.2)
Serum Creatinine, mean, (SD), mol/L
Patients completing the study
250
133.9 (51.4)
266
137.2 (52.7)
Patients with month 6
289
138.2 (57.7)
289
144.7 (93.7)
Patients with DGF
48
169.9 (77.0)
38
151.5 (54.8)
Patients without DGF
241
131.9 (51.0)
251
143.7 (98.3)
FAS DGF: Delayed graft function. MDRD: Modification of Diet in Renal Disease. and withdrawn patients with available data at 6 months after transplantation.